PNAS releases three-negative breast cancer treatment breakthrough: new immunotherapy effect is gratifying.

TextMantriu triple-negative breast cancer (TNBC) accounts for 12%-20% of all breast cancers due to estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptors 2 (HER2) are all negative expression names; Transfer; insensitive to hormone therapy and targeted treatments such as Herceptin, which can be treated with almost only chemotherapy, most patients quickly develop resistance and have a poor prognosis;This week, researchers at Northwestern University in the United States reported a new immunotherapy that significantly prolongs the survival of mice with triple-negative breast cancerthe new treatment consists of two immuno-stimulating drugs encapsulated in nanoparticles, and the mice treated with them were completely remissionable for at least 100 days, and none of the mice treated had adverse side effects or autoimmune responsesresearch will be published in the journal PNAS under the title "Tumor cell lysate-loaded immuno-e-immunoory spherical acids as therapeuticsfor da thio cancer"source: Northwestern University specifically, the nanoparticles used in the study are called "spherical nucleic acids" (SNA), which is essentially a spherical DNA that easily enters and stimulates immune cellsChad AMirkin, a professor of chemical and biomedical engineering at thewho led the study, attributed the success of the new immunotherapy to the shape and structure of nanoparticles"We have shown that the overall structure of cancer vaccines or immunotherapy , not just the active chemicals , can significantly affect their effectiveness , " he saidnew discovery opens the door to the emerging field of 'Rational Vacnology', which promises to bring new treatments for a wide range of cancers"How does the new therapy work?" Typical immunotherapy consists of one or more molecules (i.eantigens) from tumor cells and one molecule (i.ea dissertation) used to stimulate the immune systemmore advanced immunotherapy consists of antigen molecular cocktails called lysates that collect cancer cells from patientsLysates trains the immune system to recognize its target (tumor), while adjorgants enhance the body's immune response to destroy the tumorusually, doctors mix lysates with adjokiases in cell culture and inject the mixture into the patient because the therapy is a structurally ambiguous mixture, Professor Mirkin calls it "Blender Approach." more important, since Lysates and adjorlocates are not packed together, it's hard to make sure they hit the same target " is statistically statistically concerned, some cells absorb both Lysate and adjectomy, but some cells get only one of the two In order to maximize the effectiveness of immunotherapy, we need to deliver both in the most effective form or structure together to the same target cells " explains Cassandra Callmann, a postdoctoral researcher at Mirkin Labs to overcome this challenge, Professor Mirkin's team packed lysate and adjectomy in a "core" position of a "spherical nucleic acid" (SNA) in the study, they injected SNA under the skin of mice with triple-negative breast cancer After , SNAs go to the lymph nodes of the mice and then enter the target cells, releasing their transported "goods", known as lysate and adjectomy this causes an immune response within the cell to fight lysate extended survival and prevented recurrence of the innovative treatment of 9 mice with triple-negative breast cancer, six tumors were completely remissiond for 100 days with no significant side effects Although the other three mice did not achieve remission, the new treatment did inhibit their tumor growth, and they still lived longer than the control mice (all untreated mice died within 30 days) "Although not all mice have been cured, our new treatment is sure to extend life," said callmann, " Professor Mirkin and his team also found that SNA-based immunotherapy protected mice from recurrence after the mice were relieved, the team tried to implant the tumor again in the mice, but the tumor did not grow analyzed tumors in mice treated, the researchers found an increase in the number of anti-tumor cytotoxic T cells and a decrease in the number of immunosuppressive cells that prevented the immune system from fighting tumors Professor Mirkin said: "Our study shows that this new treatment provides an immune memory, and if our immunotherapy protects mice from cancer recurrence, then we may use it for prevention "Multiple Cancer Potential Therapies Although the study was conducted on triple-negative breast cancer, the researchers believe that, in theory, SNA-based immunotherapy should be an effective treatment for multiple cancers." Professor Mirkin's team plans to explore this next step in addition, he noted that he was encouraged by the fact that four SNA drugs had entered the clinical development phase , an immunotherapy developed based on the SNA variant used in this study (AST-008, an SNA structure of The TLR9 agonisant oligonucleotide) is undergoing Phase II clinical trials in patients with Merkel cell carcinoma (NCT03684785) source: Exicure is understood to be led by Chicago-based biotech company Exicure Professor Mirkin is one of the company's co-founders in addition to the field of oncology, Exicure's main SNA-based projects also cover inflammatory diseases, genetic diseases, etc References: 1 new therapy extensions breast cancer survival rate, prevents reoccurrence (Source: Northwestern University) Original title: PNAS Releases Three-Negative Breast Cancer Treatment Breakthrough: New Immunotherapy Efficacy, 67% Study Cure Rate